Search
Fate Therapeutics Inc
FATEAdd to Watchlist
2.100USD
+0.230+12.30%
Close 06/26, 16:00（ET）Quotes delayed by 15 min
242.26MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+12.30%
5 Days
+0.48%
1 Month
-6.67%
6 Months
+107.92%
Year to Date
+113.72%
1 Year
+81.03%
Key Figures
1.880Open
2.110High
13.97MVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
12.11%Turnover Ratio
1.870Prev. Close
1.862Low
26.86MTurnover
LossP/E Static
1.17P/B
0.00%Div Yield TTM
-38.01%ROA
2.66552wk High
2.48Volume Ratio
-186.26MNet Profit
115.36MShares
-1.0898EPS TTM
2.42Beta
-55.50%ROE
0.91052wk Low
13.26%Amplitude
100.00%Gross Margin
242.26MMarket Cap
-5.20Reward/Risk
5.56%Risk Rate
TradingKey Stock Score of Fate Therapeutics Inc
Currency: USD Updated: 2026-06-25Key Insights
Fate Therapeutics Inc's fundamentals are relatively stable, and its growth potential is significant.Its valuation is considered fairly valued, ranking 131 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 5.59.In the medium term, the stock price is expected to trend up.Despite a very weak stock market performance over the past month, the company shows strong technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Fate Therapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Negative
Fate Therapeutics Inc Highlights
StrengthsRisks
Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to bringing a pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients. Using its proprietary iPSC product platform, the Company has established a position in creating multiplexed-engineered master iPSC lines and in the manufacture and clinical development of off-the-shelf, iPSC-derived cell products. The Company’s pipeline includes iPSC-derived T-cell and natural killer (NK) cell product candidates, which are selectively designed, incorporate novel synthetic controls of cell function, and are intended to deliver multiple therapeutic mechanisms to patients. Its product candidates under development include FT819, FT522, FT829, FT825, FT836, and others. FT819 is its first iPSC-derived CAR T-cell product candidate. FT522 is its first iPSC-derived CAR NK cell product candidate that incorporates its novel Alloimmune Defense Receptor (ADR) technology.
Growing
The company is in a growing phase, with the latest annual income totaling USD 6.65M.
Fairly Valued
The company’s latest PE is -1.72, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 92.31M shares, decreasing 29.73% quarter-over-quarter.
Held by Bill Nygren | OAKMX
Star Investor Bill Nygren | OAKMX holds 5.22M shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.96.
Analyst Rating
Based on
12
analysts
Buy
Current Rating
5.588
Target Price
+158.68%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Fate Therapeutics Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Fate Therapeutics Inc Info
Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to bringing a pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients. Using its proprietary iPSC product platform, the Company has established a position in creating multiplexed-engineered master iPSC lines and in the manufacture and clinical development of off-the-shelf, iPSC-derived cell products. The Company’s pipeline includes iPSC-derived T-cell and natural killer (NK) cell product candidates, which are selectively designed, incorporate novel synthetic controls of cell function, and are intended to deliver multiple therapeutic mechanisms to patients. Its product candidates under development include FT819, FT522, FT829, FT825, FT836, and others. FT819 is its first iPSC-derived CAR T-cell product candidate. FT522 is its first iPSC-derived CAR NK cell product candidate that incorporates its novel Alloimmune Defense Receptor (ADR) technology.
Ticker SymbolFATE
CompanyFate Therapeutics Inc
CEOValamehr (Bahram)
Websitehttps://fatetherapeutics.com/
Related Instruments
+7.01%
+3.85%
+1.36%
+3.63%
+2.35%
+0.12%
+1.56%
+0.78%
+3.26%
+2.60%
+2.32%
+3.81%
+1.16%
+2.75%
-0.01%
0.00%
+2.06%
+1.31%
-0.17%
+1.76%Popular Instruments
51869.400
-155.300 (-0.30%)
29073.500
-381.500 (-1.29%)
7352.200
-14.600 (-0.20%)
15278.000
-473.000 (-3.00%)
69574.000
-1558.000 (-2.19%)
6207.100
-58.700 (-0.94%)
69.448
-1.896 (-2.66%)
283.780
+8.630 (+3.14%)
192.530
-3.210 (-1.64%)
4071.710
+45.560 (+1.13%)
FAQs
What is the current price of Fate Therapeutics Inc (FATE)?
The current price of Fate Therapeutics Inc (FATE) is 1.87.
What is the symbol of Fate Therapeutics Inc?
The ticker symbol of Fate Therapeutics Inc is FATE.
What is the 52-week high of Fate Therapeutics Inc?
The 52-week high of Fate Therapeutics Inc is 2.67.
What is the 52-week low of Fate Therapeutics Inc?
The 52-week low of Fate Therapeutics Inc is 0.91.
What is the market capitalization of Fate Therapeutics Inc?
The market capitalization of Fate Therapeutics Inc is 217.97M.
Is Fate Therapeutics Inc (FATE) currently rated as Buy, Hold, or Sell?
According to analysts, Fate Therapeutics Inc (FATE) has an overall rating of Buy, with a price target of 5.59.
What is the Earnings Per Share (EPS TTM) of Fate Therapeutics Inc (FATE)?
The Earnings Per Share (EPS TTM) of Fate Therapeutics Inc (FATE) is -1.15.
